Amneal Pharmaceuticals, Inc. (AMRX) Stock Forecast & Price Target
Price as of Nov 17, 2026 (intraday, delayed) · Analyst estimates retrieved Nov 12, 2026 · Source: Financial Modeling Prep (analyst estimates) (methodology)
Revenue and earnings estimates published by analysts covering Amneal Pharmaceuticals, Inc. (AMRX), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.
For Amneal Pharmaceuticals, Inc., analysts forecast revenue rising from $2.77B in 2024 to $4.53B in 2029; the average estimate for 2029 earnings per share is $1.81; with published estimates ranging from $1.73 to $1.90; 5 analysts contribute to these figures. These are forecasts published by analysts, not results.
Analyst price targets
A price target is one analyst's forecast of where a share might trade, usually over twelve months. Targets are frequently revised, they disagree with each other, and they are not a measure of what a company is worth.
Revenue forecast (USD)
The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.
Earnings per share forecast
Amneal Pharmaceuticals, Inc. (AMRX) forecast — frequently asked questions
What is the analyst price target for Amneal Pharmaceuticals, Inc.?
Analysts covering Amneal Pharmaceuticals, Inc. (AMRX) have a consensus price target of $23.33, 11.4% above the current price of $20.95. Published targets range from $20.00 to $27.00. A price target is a forecast, not a measure of value, and targets are revised often.
What are analysts forecasting for Amneal Pharmaceuticals, Inc.'s earnings?
The average analyst estimate for Amneal Pharmaceuticals, Inc. (AMRX) earnings per share in 2029 is 1.81, with individual estimates between 1.73 and 1.90.
How much revenue is Amneal Pharmaceuticals, Inc. expected to make?
Analysts forecast Amneal Pharmaceuticals, Inc. (AMRX) revenue of $4.53B in 2029, based on 2 published estimates.
How many analysts cover AMRX?
5 analysts contribute estimates for Amneal Pharmaceuticals, Inc. (AMRX). Thin coverage makes an average less reliable.
Analyst forecasts for other Drug Manufacturers - Specialty & Generic stocks
Popular Stocks
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.